Video

Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center, chief medical officer, International Myeloma Foundation, discusses unmet needs in triple-class refractory multiple myeloma.

Within the past year, the multiple myeloma armamentarium has expanded to include the novel XPO1 inhibitor selinexor (Xpovio) and the BCMA-directed antibody-drug conjugate belantamab mafodotin-blmf (Blenrep) for patients with heavily pretreated, relapsed/refractory disease. Additionally, the CD38-directed antibody isatuximab-irfc (Sarclisa) was also approved in combination with pomalidomide (Pomalyst) and dexamethasone for patients with relapsed/refractory multiple myeloma who have progressed on 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor. 

However, despite a multitude of available agents, myeloma remains incurable, Mikhael says. The majority of patients will become triple-class refractory and progress on bortezomib (Velcade), lenalidomide, pomalidomide, carfilzomib (Cabometyx), and daratumumab (Darzalex).

Treatment selection with these novel agents should be individualized for patients with triple-class refractory disease, Mikhael says. Additionally, future research efforts should aim to evaluate these therapies in combinations and earlier on in the treatment course.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity